KRAS and pancreatic adenocarcinoma: As for KRAS, it is a small GTPase (21 kDa) and 95% of PAAD patients had KRAS mutations [11], which caused KRAS to be constitutively activated resulting in uncontrolled cell proliferation and other processes that led to the development and spread of cancer [12].